NASDAQ: MRSNMersana Therapeutics Inc Stock
$0.37-0.01 (-2.63%)
Updated Apr 29, 2025
MRSN Price
$0.37
Fair Value Price
N/A
Market Cap
$45.99M
52 Week Low
$0.26
52 Week High
$3.63
P/E
-0.66x
P/B
-4.84x
P/S
4.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$40.50M
Earnings
-$69.19M
Gross Margin
100%
Operating Margin
-160.26%
Profit Margin
-170.9%
Debt to Equity
-16.21
Operating Cash Flow
-$82M
Beta
1.63
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MRSN Overview
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MRSN's potential to beat the market
- MRSN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MRSN
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important MRSN news, forecast changes, insider trades & much more!
MRSN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MRSN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRSN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRSN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MRSN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MRSN due diligence checks available for Premium users.
Valuation
MRSN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.66x
Industry
-158.75x
Market
29.19x
MRSN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.84x
Industry
4.37x
MRSN's financial health
Profit margin
Revenue
$16.4M
Net Income
-$14.1M
Profit Margin
-86.3%
MRSN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MRSN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$144.7M
Liabilities
$154.2M
Debt to equity
-16.21
MRSN's short-term assets ($136.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRSN's short-term assets ($136.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRSN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MRSN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.3M
Investing
$50.0M
Financing
-$1.9M
MRSN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MRSN vs Biotech Stocks
Mersana Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.